Wide Ranks

BCAX

Bicara Therapeutics Inc.

20.96

Top Statistics
Market Cap 1 B Forward PE -14.23 Revenue Growth 0.00 %
Current Ratio 36.01 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -8.94 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 520 M Total Cash Per Share 9.57 Total Debt 445000
Total Debt To Equity 0.0870 Current Ratio 36.01 Book Value Per Share 9.37
All Measures
Short Ratio 664.00 % Message Board Id finmb_674698236 Shares Short Prior Month 1 M
City Boston Uuid 89c17e6e-41f3-3d01-85f9-cd0e48aa9b6d Previous Close 20.45
First Trade Date Epoch Utc 1 B Book Value 9.37 Total Debt 445000
Volume 184495 Price To Book 2.24 Fifty Two Week Low 17.41
Total Cash Per Share 9.57 Shares Short Previous Month Date 1 B Target Median Price 37.19
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 40.06
Net Income To Common -59478000 Ask 21.10 Implied Shares Outstanding 54 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 376520
Average Volume10days 376520 Total Cash 520 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0626 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 20.45 Target Low Price 36.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 22.48 Open 20.42
Dividend Yield 0.00 % State MA Time Zone Short Name EST
Trailing Eps -1.09 Day Low 19.66 Address1 116 Huntington Avenue
Shares Outstanding 54 M Price Hint 2 Target High Price 47.00
Website https://www.bicara.com 52 Week Change -0.1047 Average Volume 450031
Forward Eps -1.61 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 3596.10 % Is_sp_500 False Regular Market Day High 21.50
Profit Margins 0.00 % Debt To Equity 0.0870 Fifty Two Week High 28.09
Day High 21.50 Shares Short 1 M Regular Market Open 20.42
Industry Key biotechnology Bid 20.56 Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0381 Operating Cashflow -52755000
Currency USD Time Zone Full Name America/New_York Market Cap 1 B
Is_nasdaq_100 False Zip 02116 Quote Type EQUITY
Industry Biotechnology Long Name Bicara Therapeutics Inc. Regular Market Day Low 19.66
Held Percent Institutions 0.7249 Current Price 20.96 Address2 Suite 703
Enterprise To Ebitda -8.94 Financial Currency USD Current Ratio 36.01
Industry Disp Biotechnology Number Of Analyst Opinions 3 Country United States
Float Shares 31 M Two Hundred Day Average 22.70 Enterprise Value 620 M
Forward PE -14.23 Regular Market Volume 184495 Ebitda -69384000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.

Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

The company was incorporated in 2018 and is based in Boston, Massachusetts.